Biobanking Market Overview
As per MRFR analysis, the Biobanking Market Size was estimated at 4.93 (USD Billion) in 2023.The Biobanking Market is expected to grow from 5.14(USD Billion) in 2024 to 8 (USD Billion) by 2035. The Biobanking Market CAGR (growth rate) is expected to be around 4.11% during the forecast period (2025-2035).
Key Biobanking Market Trends Highlighted
Due to a number of important industry drivers, the global biobanking market is now expanding significantly. Biobanking has received a lot of attention as a vital resource for research and development because of the rising incidence of chronic diseases and the growing need for tailored therapy.
In order to improve healthcare outcomes, governments around the world are actively supporting biobanking efforts through financial and regulatory frameworks. Collaborations between educational institutions, pharmaceutical companies, and biobanks support this increased investment by making it easier for biological samples to be shared for study, which spurs innovation in the sector.
The integration of cutting-edge technology, such artificial intelligence and data analytics, which can improve the management and analysis of biobanked samples, is one opportunity to be investigated or seize in the global biobanking market. Precision medicine offers biobanks a rare opportunity to supply high-quality biological samples that are essential for developing customized treatments.
Furthermore, extending biobanks into underdeveloped areas can help meet regional research demands and promote improvements in global health. Recent trends show that participant permission and ethical issues are becoming increasingly important when it comes to sample collection and use.
In order to maintain donor confidence and openness and to comply with local regulations, biobanks are progressively implementing strong consent models.
Furthermore, there is a trend toward the creation of population-based biobanks, which encourage the gathering of varied samples to reflect various demographic groups, thereby advancing inclusive research and enhancing health equity on a worldwide scale.
This emphasis on moral behavior and diversity strengthens the biobanking industry's entire framework and its function in tackling global public health issues.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Biobanking Market Drivers
Increasing Research and Development Activities in Biotechnology
The Global Biobanking Market is significantly driven by the rising activities in Research and Development within the biotechnology sector. Governments and private organizations are heavily investing in biotech R&D to discover new therapies and personalized medicine.
For example, the National Institutes of Health (NIH) in the United States has reported a continuous increase in funding for biotech R&D, reaching approximately 42 billion USD recently. This substantial flow of investment fosters the expansion of biobanks, which are essential for storing biological samples required for innovative research.
Additionally, institutions like the European Molecular Biology Laboratory are collaborating globally, providing access to biobanks that enhance the scope and efficiency of ongoing research projects. This growth not only assures a greater number of biological samples being banked but also enhances the potential for groundbreaking medical discoveries that rely on biobanking.
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases globally, including diabetes, cardiovascular diseases, and cancers, is a strong driver for the Global Biobanking Market.
According to the World Health Organization (WHO), chronic diseases are responsible for approximately 71% of all deaths worldwide, highlighting an alarming trend over the years. This surge prompts healthcare systems and research organizations to seek extensive biological materials for developing effective treatments and preventive measures.
For instance, established organizations like the American Cancer Society are expanding their initiatives in biobanking to collect samples for research aimed at understanding cancer diagnosis and treatment better, contributing to the growth of biobanks worldwide.
Advancements in Biobanking Technologies
Technological advancements are playing a pivotal role in the growth of the Global Biobanking Market. Innovations in biobanking technologies, such as automated sample processing systems, advanced cryopreservation methods, and data management systems, have significantly improved sample integrity and efficiency.
For example, research conducted by the National Academy of Sciences emphasizes the effectiveness of automated cryopreservation technology, which reduces human error and ensures better sample quality.
Companies like Thermo Fisher Scientific are at the forefront, developing state-of-the-art equipment tailored for biobanks. The continuous evolution in technology not only enhances the operational capabilities of biobanks but also attracts more institutions to integrate biobanking as part of their research ecosystem.
Biobanking Market Segment Insights
Biobanking Market Sample Type Insights
The Global Biobanking Market was structured into various Sample Type segments, providing extensive insights into its dynamics and valuation trends.
In 2024, the market anticipates substantial contributions from these samples, with Blood Products valued at 1.24 USD Billion, highlighting its dominant role in biobanking. Blood Products led due to their critical importance in diagnostics and therapeutic applications, being essential in numerous research protocols.
Tissues, valued at 1.03 USD Billion in 2024, were also a significant Sample Type, facilitating advances in regenerative medicine and cancer research, thus playing a central role in understanding complex biological processes.
Cells, generating a value of 1.07 USD Billion, were integral to research and development, particularly in stem cell research and personalized medicine, emphasizing their growing relevance in clinical applications.
Nucleic Acids represented another vital segment with a valuation of 1.37 USD Billion, underscoring their importance in genetic research and molecular diagnostics, which have seen rapid advancements in recent years.
Finally, Microbiome Samples, valued at 0.43 USD Billion, while the smallest segment, gained traction as they opened new avenues for understanding the human microbiome's role in health and disease, which is an evolving area in biobanking.
Collectively, these segments contribute to a nuanced understanding of the Global Biobanking Market, with Blood Products and Nucleic Acids showing particularly strong performance, which is indicative of their essential roles in research and their increasing applications in clinical settings.
The industry's growth is fueled by advancements in technology, increasing research investments, and rising demand for personalized medicine, aiming to optimize patient outcomes and enhance therapeutic developments across a global scale.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Biobanking Market Application Insights
The Global Biobanking Market, focusing on the Application segment, is witnessing notable growth, reflecting its essential role in advancing medical research and therapies.
The Applications segment encompasses key areas such as Research and Development, Clinical Trials, Personalized Medicine, and Regenerative Medicine, with Research and Development being vital in propelling innovative treatments and enhancing our understanding of diseases.
Clinical Trials heavily rely on biobanks for sourcing biological samples, facilitating the development of safe and effective therapies. Personalized Medicine is gaining traction as healthcare shifts towards tailored treatments based on genetic information, making biobanks indispensable for accessing relevant biological data.
Regenerative Medicine leverages biobanking resources to advance cell-based therapy and tissue engineering efforts. Overall, the Global Biobanking Market segmentation reflects a robust framework supporting research efforts, addressing the growing need for biological repositories, and paving the way for breakthroughs in healthcare.
The diverse applications from these areas create significant opportunities for market growth while also presenting challenges in standardization and regulation.
Biobanking Market End-Use Insights
The Global Biobanking Market showcases significant diversity in its End-use segment, comprising major players such as Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations.
Academic Research Institutions are pivotal, driving innovation and advancements through the utilization of biobanked samples for Research and Development, as they are primarily focused on scientific inquiries. Biotechnology Companies leverage these biobanks to not only develop but also test new therapies and vaccines, hence they play an essential role in addressing public health challenges.
Pharmaceutical Companies predominantly utilize biobanking for drug discovery, ensuring the efficacy and safety of new medications, making them integral to the lifecycle of pharmaceutical advancements.
Government Organizations support this landscape through funding initiatives and regulatory frameworks that facilitate the collaboration and ethical management of biobanks, thereby enhancing public trust and accessibility to biobanking resources.
As the biobanking industry continues to evolve, these segments drive market growth by unlocking new research opportunities, improving healthcare outcomes, and addressing global health concerns. Additionally, the rising integration of technology in biobanking practices offers further opportunities for innovation and operational efficiency within these key end-use sectors.
Biobanking Market Storage Type Insights
Within this market, the Storage Type segment plays a vital role, incorporating various techniques such as Vapor Phase Storage, Liquid Phase Storage, and Cryopreservation Storage, each crucial for maintaining sample integrity. Vapor Phase Storage is gaining traction due to its ability to provide low-temperature preservation without direct contact with liquid nitrogen, reducing risks of contamination.
Liquid Phase Storage, while traditional, still holds significant importance as it allows for easier sample retrieval. Cryopreservation Storage dominates due to its effectiveness in preserving cells, tissues, and other biological materials for long-term storage, facilitating advancements in Research and Development across multiple sectors.
The Global Biobanking Market statistics reveal that the emphasis on biobanking practices aligns with heightened awareness around personalized medicine and genetic research, presenting valuable opportunities for market expansion. However, challenges such as regulatory compliance and technological advancements need to be addressed to ensure the sustained growth of this industry.
Biobanking Market Regional Insights
The Global Biobanking Market saw significant growth, particularly across its regional segments, with North America leading the way. In 2024, North America was valued at 2.2 USD Billion and is set to reach 3.3 USD Billion by 2035, reflecting its majority holding in the market due to advanced healthcare infrastructure and robust Research and Development activities.
Europe followed closely with a valuation of 1.4 USD Billion in 2024, increasing to 2.2 USD Billion by 2035, benefiting from a strong emphasis on biobanking in biomedical research initiatives.
The Asia-Pacific (APAC) region was also enhancing its position, expected to grow from 1.1 USD Billion in 2024 to 1.8 USD Billion by 2035, driven by increasing investments in biotechnology and growing public awareness.
South America, albeit smaller, showed promise with a valuation of 0.2 USD Billion in 2024, projected to reach 0.3 USD Billion by 2035, as the region focuses on improving healthcare systems and biobanking capabilities.
Meanwhile, the Middle East and Africa (MEA) segment, valued at 0.24 USD Billion in 2024 and growing to 0.4 USD Billion by 2035, highlighted the rising interest and investment in biobanking to support health research and disease prevention.
Understanding the Global Biobanking Market segmentation helped identify key trends, growth drivers, and opportunities in various regions, enabling stakeholders to leverage insights effectively.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Biobanking Market Key Players and Competitive Insights
The Global Biobanking Market has seen significant growth due to advancements in biotechnology, increasing demand for personalized medicine, and the need for advanced research support in addressing various diseases. Biobanks play an essential role in modern research, providing critical bioprocessing and storage solutions for biological samples such as tissues, DNA, and other biological materials.
Competitive insights reveal a landscape marked by innovative strategies and diverse business models aimed at catering to the evolving needs of researchers and healthcare providers. Factors like regulatory requirements, quality control, and technological advancements in biobanking practices are critical in shaping competitive dynamics within this market.
Companies are increasingly focusing on strategic partnerships, technological innovations, and expansion of their operational capabilities to secure a competitive advantage.
Novogene has established itself as a prominent player in the Global Biobanking Market, particularly noted for its genomic services and bioinformatics capabilities that complement biobanking applications. This company is recognized for its advanced genomic sequencing technology and data analysis expertise, which enhance the value derived from biobanked samples.
By offering comprehensive solutions that integrate sample management and genomic analysis, Novogene stands out in facilitating high-quality research outcomes. The company’s commitment to innovation is reflected in its investments in improving data management systems and sample preservation techniques.
Its extensive network and partnerships enable it to maintain a robust presence in global markets, establishing trust and reliability among researchers and healthcare entities relying on biobanks for their studies.
BD, or Becton, Dickinson and Company, has a substantial footprint in the Global Biobanking Market with its focus on diagnostic and laboratory solutions. The company is well-known for its extensive range of key products, including sample collection devices, preservation solutions, and bioprocessing technologies tailored for use within biobanks.
BD’s strengths lie in its innovative technologies and deep expertise in laboratory operations, which enhance the storage and processing of biological samples. Additionally, BD has a history of strategic mergers and acquisitions, allowing it to integrate complementary technologies and services that bolster its biobanking portfolio.
By continuously advancing its product offerings and aligning them with current market needs, BD maintains a competitive edge within the sector, fostering collaborative relationships with research institutions and healthcare organizations globally to support biobanking initiatives.
Key Companies in the Biobanking Market Include
- Novogene
- BD
- Thermo Fisher Scientific
- Global Biobank
- Oxford Biomedica
- VWR
- Biobase
- Sampled
- Celerion
- Qiagen
- MilliporeSigma
- Libra Bioscience
- STEMCELL Technologies
- Beckman Coulter
- Tecan
Biobanking Market Developments
The Global Biobanking Market has seen significant developments recently, driven by advancements in biobanking technologies and increasing demand for personalized medicine. Notably, in August 2023, Thermo Fisher Scientific announced the expansion of its biobanking platform, enhancing cryopreservation solutions, which is anticipated to increase efficiency in sample preservation.
In September 2023, BD launched an innovative biospecimen collection system aimed at improving sample quality for research purposes. Mergers and acquisitions are also shaping the market, with Novogene acquiring a smaller biobanking firm in June 2023 to expand its genomic sequencing capabilities, further diversifying its offerings.
Market valuations for companies such as Qiagen and Sampled have grown significantly, reflecting a broader trend of investment in biobanking operations. The global biobanking sector is expected to benefit from rising healthcare expenditures and growing research initiatives aimed at understanding genetic diseases and treatments.
The ongoing collaboration between Oxford Biomedica and various research institutions is enhancing the repository of biological samples, thereby bolstering the infrastructure for innovative medical research. Over the past two years, the increasing integration of artificial intelligence in biobanking practices has driven growth and improved operational efficiencies across the sector.
Biobanking Market Segmentation Insights
Biobanking Market Sample Type Outlook
- Blood Products
- Tissues
- Cells
- Nucleic Acids
- Microbiome Samples
Biobanking Market Application Outlook
- Research and Development
- Clinical Trials
- Personalized Medicine
- Regenerative Medicine
Biobanking Market End-Use Outlook
- Academic Research Institutions
- Biotechnology Companies
- Pharmaceutical Companies
- Government Organizations
Biobanking Market Storage Type Outlook
- Vapor Phase Storage
- Liquid Phase Storage
- Cryopreservation Storage
Biobanking Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric Source: |
Details |
| MARKET SIZE 2023 |
4.93(USD Billion) |
| MARKET SIZE 2024 |
5.14(USD Billion) |
| MARKET SIZE 2035 |
8.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) |
4.11% (2025 - 2035) |
| REPORT COVERAGE |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR |
2024 |
| MARKET FORECAST PERIOD |
2025 - 2035 |
| HISTORICAL DATA |
2019 - 2024 |
| MARKET FORECAST UNITS |
USD Billion |
| KEY COMPANIES PROFILED |
Novogene, BD, Thermo Fisher Scientific, Global Biobank, Oxford Biomedica, VWR, Biobase, Sampled, Celerion, Qiagen, MilliporeSigma, Libra Bioscience, STEMCELL Technologies, Beckman Coulter, Tecan |
| SEGMENTS COVERED |
Sample Type, Application, End Use, Storage Type, Regional |
| KEY MARKET OPPORTUNITIES |
Increased demand for personalized medicine, Growing investment in regenerative medicine, Advancements in genomic research technologies, Expansion of biobank partnerships and collaborations, Rising prevalence of chronic diseases |
| KEY MARKET DYNAMICS |
increasing demand for personalized medicine, technological advancements in biobanking, stringent regulatory frameworks, rising investment in research, growing awareness of biobanks |
| COUNTRIES COVERED |
North America, Europe, APAC, South America, MEA |
Biobanking Market Highlights:
Frequently Asked Questions (FAQ) :
The Global Biobanking Market is expected to be valued at 5.14 USD billion in 2024.
By 2035, the Global Biobanking Market is projected to reach a value of 8.0 USD billion.
The expected CAGR for the Global Biobanking Market from 2025 to 2035 is 4.11%.
North America is expected to hold the largest market share with a value of 2.2 USD billion in 2024.
The market size for the Global Biobanking Market in Europe is expected to reach 2.2 USD billion by 2035.
Key players in the Global Biobanking Market include Novogene, BD, Thermo Fisher Scientific, and Oxford Biomedica.
The market size for Blood Products is expected to be 1.9 USD billion by 2035.
The market size for Tissues in the Global Biobanking Market is valued at 1.03 USD billion in 2024.
The market in the APAC region is projected to grow to 1.8 USD billion by 2035.
The expected market size for Microbiome Samples by 2035 is 0.9 USD billion.
